Noncarriers had elevated CBC and nonbreast/ovarian cancer SIRs, which were lower than the corresponding BRCA1-or BRCA2-specific SIRs (CBC: SIR, 3.03 [95% CI, 2.67 to 3.43]; nonbreast/ovarian: SIR, 1.26 [95% CI, 1.14 to 1.38]). This evidence concerns the gene BRCA2 and ovarian cancer.